- Home
- SLN vs OLMA Comparison
SLN vs OLMA Comparison
Compare SLN & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- OLMA
- Stock Information
- Founded
- SLN 1994
- OLMA 2006
- Country
- SLN United Kingdom
- OLMA United States
- Employees
- SLN N/A
- OLMA N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- SLN Health Care
- OLMA Health Care
- Exchange
- SLN Nasdaq
- OLMA Nasdaq
- Market Cap
- SLN 352.2M
- OLMA 383.1M
- IPO Year
- SLN N/A
- OLMA 2020
- Fundamental
- Price
- SLN $4.79
- OLMA $4.99
- Analyst Decision
- SLN Buy
- OLMA Strong Buy
- Analyst Count
- SLN 4
- OLMA 4
- Target Price
- SLN $46.25
- OLMA $28.33
- AVG Volume (30 Days)
- SLN 339.1K
- OLMA 1.0M
- Earning Date
- SLN 02-27-2025
- OLMA 03-10-2025
- Dividend Yield
- SLN N/A
- OLMA N/A
- EPS Growth
- SLN N/A
- OLMA N/A
- EPS
- SLN N/A
- OLMA N/A
- Revenue
- SLN $21,773,221.00
- OLMA N/A
- Revenue This Year
- SLN N/A
- OLMA N/A
- Revenue Next Year
- SLN $104.98
- OLMA N/A
- P/E Ratio
- SLN N/A
- OLMA N/A
- Revenue Growth
- SLN N/A
- OLMA N/A
- 52 Week Low
- SLN $4.06
- OLMA $4.60
- 52 Week High
- SLN $27.72
- OLMA $16.62
- Technical
- Relative Strength Index (RSI)
- SLN 41.33
- OLMA 38.98
- Support Level
- SLN $4.71
- OLMA $4.94
- Resistance Level
- SLN $5.16
- OLMA $5.34
- Average True Range (ATR)
- SLN 0.47
- OLMA 0.42
- MACD
- SLN 0.08
- OLMA -0.03
- Stochastic Oscillator
- SLN 32.74
- OLMA 11.39
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.